

January 23, 2020



# Calyxt Appoints Bobby Williams as Gene Editing Director to Expand Innovation and Product Pipeline

ROSEVILLE, Minn.--(BUSINESS WIRE)-- [Calyxt, Inc.](#) (NASDAQ: CLXT), a plant-based technology company, has appointed Bobby Williams, Ph.D. to the newly created role of Director of Gene Editing to further expand Calyxt's innovation, product pipeline, and trait discovery efforts and inform product advancement decisions.

Dr. Williams has been on the forefront of advancements in plant sciences, and is an expert in the gene editing field. His accomplishments include developing new gene silencing technology and leading efforts to discover small RNAs to precisely engineer beneficial crop traits. In addition, Dr. Williams led gene discovery initiatives to improve crop traits to support sustainability, specifically drought resistance, improved nitrogen efficiency and yield enhancement.

"The addition of Bobby to the R&D team empowers us to further leverage our technology and develop next generation products to solve unmet consumer, marketplace and environmental demands," said Travis Frey, chief technology officer with Calyxt. "A talented and disciplined inventor, Bobby can immediately contribute to our pipeline with his gene editing and discovery prowess and innovative thinking," concluded Frey.

"Calyxt is an innovation platform company and we believe the successful commercial launch of our HO soybean products proves there is demand for gene-edited products," said Jim Blome, chief executive officer of Calyxt. "The potential benefits of gene-edited products to foodservice and food manufacturing companies (performance), consumers (health) and the planet (sustainability) are significant. We aim, through science, to benefit both people and planet and look forward to accelerating this initiative through Bobby's addition," concluded Blome.

With more than 15 years of expertise in the agriculture and seed industry, Dr. Williams most recently served as Senior Research Manager at Corteva Agriscience, where he led multiple trait discovery efforts and cross functional teams through field advancements. Prior to Corteva, Dr. Williams was a Helen Hay Whitney post-doctoral fellow at UC Berkeley studying *Drosophila* development under Gerald Rubin, Ph.D. He earned his Ph.D. in Biology at the California Institute of Technology in Pasadena, CA where he focused on plant developmental genetics with Elliot Meyerowitz, Ph.D.

## About Calyxt

Calyxt (NASDAQ: CLXT), based in Roseville, Minnesota is a plant-based technology company that utilizes our patented breeding technology to make the food you love a healthier choice. The care we take extends beyond nutritional value. We partner with

farmers and food companies to deliver traceable plant-based products developed to be healthier and more sustainable than their conventional counterparts. We use cutting edge plant breeding techniques to develop products that help improve diets by reducing bad fats, allergens and toxins. Today oil from our high oleic soybean plants has lower saturated fats than commodity soybean oil. We are also developing high fiber wheat designed to provide an excellent source of daily fiber when incorporated into wheat-based foods. We continuously pursue innovation to deliver good food that is good for you. For further information, please visit our website at [www.calyxt.com](http://www.calyxt.com).

### **Calyxt Forward-Looking Statements**

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200123005457/en/>

### **Media contact**

Trina Lundblad, Director of Corporate Communications

Phone: +1 (612) 790-0514

email: [media@calyxt.com](mailto:media@calyxt.com)

### **Investor Relations contact**

Chris Tyson

Managing Director

MZ Group – MZ North America

(949) 491-8235

[CLXT@mzgroup.us](mailto:CLXT@mzgroup.us)

[www.mzgroup.us](http://www.mzgroup.us)

Source: Calyxt, Inc.